% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Szalontai:300835,
      author       = {J. Szalontai and T. Szarvas$^*$ and M. Miszczyk and P.
                      Nyirády and S. F. Shariat and T. Fazekas},
      title        = {{T}oxicities of {PARP} inhibitors in genitourinary
                      cancers.},
      journal      = {Current opinion in urology},
      volume       = {35},
      number       = {4},
      issn         = {0963-0643},
      address      = {London},
      publisher    = {Lippincott Williams $\&$ Wilkins},
      reportid     = {DKFZ-2025-00946},
      pages        = {467-471},
      year         = {2025},
      note         = {2025 Jul 1;35(4):467-471},
      abstract     = {Recent advancements in the understanding of the genetic
                      background of genitourinary cancers allowed for a successful
                      introduction of targeted antitumor agents to prostate cancer
                      (PCa) treatment. Inhibitors of the poly ADP-ribose
                      polymerase enzyme (PARPi) transformed the treatment
                      landscape of metastatic prostate cancer, and being
                      increasingly studied in earlier disease stages. However,
                      they are associated with nonnegligible toxicity, therefore,
                      we aimed to summarize their side-effect profile in patients
                      with PCa.Hematologic toxicities, particularly anemia,
                      thrombocytopenia, and neutropenia are among the most common
                      and serious adverse events associated with PARPi,
                      highlighting the need for regular blood count monitoring.
                      Nonhematologic side effects, including fatigue, nausea,
                      vomiting, diarrhea, and constipation, are common, and can be
                      mitigated with supportive interventions like dietary
                      modifications, antiemetics, or stool management techniques.
                      Special attention should be given to patients with
                      therapy-resistant or persistent cytopenia, in whom bone
                      marrow biopsy should be considered, as it can indicate
                      myelodysplastic syndrome and acute myeloid leukemia.PARP
                      inhibitors represent a major advancement in the management
                      of metastatic prostate cancer, offering a significant
                      survival benefit in applicable cases. However, patients need
                      to be carefully selected and informed, to allow for optimal
                      balancing between the benefits and nonneglectable risks of
                      severe toxicities. Better understanding of PARPi toxicity
                      profile can improve personalized decision-making and enhance
                      treatment compliance, through raising patients' awareness
                      about the possible side effects of PARPi.},
      subtyp        = {Review Article},
      keywords     = {BRCA (Other) / adverse event (Other) / anemia (Other) /
                      fatigue (Other) / genetic test (Other) / niraparib (Other) /
                      olaparib (Other) / poly ADP-ribose polymerase inhibitors
                      (Other) / prostate cancer (Other) / side effects (Other) /
                      talazoparib (Other) / toxicity (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40336260},
      doi          = {10.1097/MOU.0000000000001297},
      url          = {https://inrepo02.dkfz.de/record/300835},
}